COMPARATIVE ANALYSIS OF THE GLOMERULAR FILTRATION RATE EFFECT ON THE COURSE OF COVID-19 IN PATIENTS WITH CORONARY HEART DISEASE WITH AND WITHOUT CONCOMITANT CORONAVIRUS DISEASE
DOI:
https://doi.org/10.61751/ijmmr.2413-6077.2023.1.15Keywords:
arterial hypertension, risk factors, comorbidity, mortalityAbstract
The research relevance is determined by the COVID-19 pandemic, which has led to serious medical consequences, including high levels of infectiousness, development of diseases accompanied by complications of kidney and cardiovascular system function, and increased mortality. Therefore, the research aims to study and compare the impact of glomerular filtration rate on the course of COVID-19 in patients with and without coronary heart disease. A retrospective analysis of 410 patients with coronavirus was conducted, who were divided into 2 groups: those with chronic coronary heart disease and those without this disease. During the hospital period (14.7 ± 5.3 days), the composite endpoint of all-cause and cardiovascular deaths in combination with major adverse cardiovascular events was assessed. The thresholds for glomerular filtration rate associated with an increase in the incidence of the composite endpoint were determined: for patients with COVID-19, less than 35 mL/min×1.73 m2 (p<0.01); for patients with coronary heart disease and COVID-19, less than 60 mL/min×1.73 m2 (p<0.01). Independent predictors of decreased renal filtration capacity in patients in group 1 were: age over 65 years, type 2 diabetes mellitus, high cholesterol, D-dimer, C-reactive protein, and ferritin. Patients in group 2 were adversely affected by type 2 diabetes mellitus, arterial hypertension, and high levels of D-dimer and C-reactive protein (p < 0.05). The difference was explained by the influence of the applied therapy on the anticoagulant and renin-angiotensin systems. This study will allow to stratify patients with coronavirus in terms of renal impairment and risk factors, as well as to identify effective strategies for their management depending on the glomerular filtration rate
Received: 13.02.2023 | Revised: 21.04.2023 | Accepted: 30.05.2023
References
Matskevych V, Kamyshnyi O, Vasylyk VM, Grynovska MB, Lenchuk T, Fishchuk R, et al. Morphological prediction of lethal outcomes in the evaluation of lung tissue structural changes in patients on respiratory support with СOVID-19: Ukrainian experience. Pathol Res Pract. 2023;245:154471. DOI: 10.1016/j.prp.2023.154471
Seriakova I, Yevtushenko V, Kramarov S, Palatna L, Shpak I, Kaminska T. Clinical course of COVID-19 in hospitalized children of Ukraine in different pandemic periods. Eur Clin Respir J. 2022;9(1):2139890. DOI: 10.1080/20018525.2022.2139890
Shishkin A, Lhewa P, Yang C, Gankin Y, Chowell G, Norris M, et al. Excess mortality in Ukraine during the course of COVID-19 pandemic in 2020-2021. Sci Rep. 2023;13(1):6917. DOI: 10.1038/s41598-023-33113-2
Coronavirus in Ukraine [document on the Internet]. MinFin [cited 2023 Aug 26]. Available from: https://index.minfin.com.ua/ua/reference/coronavirus/ukraine/
Chumachenko D, Chumachenko T. Impact of war on the dynamics of COVID-19 in Ukraine. BMJ Global Health. 2022;7:e009173. DOI: 10.1136/bmjgh-2022-009173
Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A, et al. Long-COVID and post-COVID health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4):700. DOI: 10.3390/v13040700
Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345–57. DOI: 10.1080/14787210.2020.1822737
Lawal IO, Kgatle MM, Mokoala K, Farate A, Sathekge MM. Cardiovascular disturbances in COVID-19: An updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. BMC Cardiovasc Disord. 2022;22:93. DOI: 10.1186/s12872-022-02534-8
Salabei JK, Asnake ZT, Ismail ZH, Charles K, Stanger GT, Abdullahi AH, et al. COVID-19 and the cardiovascular system: An update. Am J Med Sci. 2022;364(2):139–47. DOI: 10.1016/j.amjms.2022.01.022
Mohamadi Yarijani Z, Najafi H. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. Biomed Pharmacother. 2021;142:111966. DOI: 10.1016/j.biopha.2021.111966
Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. A global picture: Therapeutic perspectives for COVID-19. Immunotherapy. 2022;14(5):351–71. DOI: 10.2217/imt-2021-0168
Edmonston DL, Pun PH. Coronary artery disease in chronic kidney disease: Highlights from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 2020;97(4):642–44. DOI: 10.1016/j.kint.2019.12.010
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425
Ministry of Health of Ukraine. On Approval of the Protocol “Provision of medical care for the treatment of coronavirus disease (COVID-19)” [Internet]. 2020 [cited 2023 Aug 28]. Order No. 762/2020. 2020 April 2. Available from: https://zakon.rada.gov.ua/rada/show/v0762282-20?lang=en#Text
The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. Available from: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/
Mahalingasivam V, Su G, Iwagami M, Davids MR, Wetmore JB, Nitsch D. COVID-19 and kidney disease: Insights from epidemiology to inform clinical practice. Nat Rev Nephrol. 2022;18:485–98. DOI: 10.1038/s41581-022-00570-3
Han X, Ye Q. Kidney involvement in COVID-19 and its treatments. J Med Virol. 2021;93(3):1387–95. DOI: 10.1002/jmv.26653
Liakopoulos V, Roumeliotis S, Papachristou S, Papanas N. COVID-19 and the kidney: Time to take a closer look. Int Urol Nephrol. 2022;54(5):1053–57. DOI: 10.1007/s11255-021-02976-7
Amann K, Boor P, Wiech T, Singh J, Vonbrunn E, Knöll A, et al. COVID-19 effects on the kidney. Pathologe. 2021;42(2):183–87. DOI: 10.1007/s00292-020-00899-1
Yang L, Li J, Wei W, Yi C, Pu Y, Zhang L, et al. Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews. Front Public Health. 2022;10:963667. DOI: 10.3389/fpubh.2022.963667
Brogan M, Ross MJ. COVID-19 and kidney disease. Annu Rev Med. 2023;74:1–13. DOI: 10.1146/annurev-med-042420-104753
Wetmore JB. Understanding the burden of the COVID-19 pandemic for people with kidney disease. Am J Kidney Dis. 2021;78(6):777–79. DOI: 10.1053/j.ajkd.2021.08.006
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):16–25. DOI: 10.1016/j.jinf.2020.04.021
Shah S, Sparks MA. COVID-19 and the kidney community: Coalescing in crisis. Adv Chronic Kidney Dis. 2020;27(5):362–64. DOI: 10.1053/j.ackd.2020.10.001
Podestà MA, Valli F, Galassi A, Cassia MA, Ciceri P, Barbieri L, et al. COVID-19 in chronic kidney disease: The impact of old and novel cardiovascular risk factors. Blood Purif. 2021;50(6):740–49. DOI: 10.1159/000514467
Theofilis P, Vordoni A, Kalaitzidis RG. COVID-19 and kidney disease: A clinical perspective. Curr Vasc Pharmacol. 2022;20(4):321–25. DOI: 10.2174/1570161120666220513103007
Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, et al. Incidence and outcomes of COVID-19 in people with CKD: A systematic review and meta-analysis. Am J Kidney Dis. 2021;78(6):804–15. DOI: 10.1053/j.ajkd.2021.07.003
May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 2021;100(6):1303–15. DOI: 10.1016/j.kint.2021.07.015
Smolander J, Bruchfeld A. COVID-19 and kidney disease. Lakartidningen. 2020;117:20110. Available from: https://pubmed.ncbi.nlm.nih.gov/32658300/
Copur S, Berkkan M, Basile C, Tuttle K, Kanbay M. Post-acute COVID-19 syndrome and kidney diseases: What do we know? J Nephrol. 2022;35(3):795–5. DOI: 10.1007/s40620-022-01296-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Сергій Євгенович Мостовий

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.








